Skip to main content
SpringerLink
Log in

SMC says 'yes' to three treatments . . .

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • , et al. SMC advice: colestilan (BindRen); dapagliflozin + metformin (Xigduo); lubiprostone, 24 micrograms soft capsules (Amitiza); ocriplasmin (Jetrea); olodaterol 2.5 microgram solution for inhalation (Striverdi Respimat); racecadotril (Hidrasec); tocilizumab (RoActemra); umeclidinium/vilanterol (Anoro). Internet Document : 11 Aug 2014. Available from: URL: http://www.scottishmedicines.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

SMC says 'yes' to three treatments . . .. PharmacoEcon Outcomes News 710, 34 (2014). https://doi.org/10.1007/s40274-014-1507-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1507-6

Search

Navigation